| 2.475 0.035 (1.43%) | 11-02 15:05 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.97 | 1-year : | 3.24 |
| Resists | First : | 2.54 | Second : | 2.77 |
| Pivot price | 2.34 |
|||
| Supports | First : | 2.16 | Second : | 1.8 |
| MAs | MA(5) : | 2.48  |
MA(20) : | 2.39 |
| MA(100) : | 3.18 |
MA(250) : | 3.42 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 59.8 |
D(3) : | 62 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 5.44 | Low : | 2.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RCKT ] has closed below upper band by 30.7%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.57 - 2.59 | 2.59 - 2.6 |
| Low: | 2.34 - 2.35 | 2.35 - 2.37 |
| Close: | 2.42 - 2.44 | 2.44 - 2.46 |
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.
Thu, 15 Oct 2026
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference - Business Wire
Tue, 06 Oct 2026
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital - Business Wire
Tue, 22 Sep 2026
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? - Yahoo Finance
Tue, 15 Sep 2026
Three patients count toward Rocket’s 12-patient gene therapy trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 110 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 91.8 (%) |
| Shares Short | 15,050 (K) |
| Shares Short P.Month | 14,710 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.5 % |
| Return on Equity (ttm) | -4.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -170 (M) |
| Levered Free Cash Flow | 86 (M) |
| PE Ratio | -14.33 |
| PEG Ratio | 0 |
| Price to Book value | 0.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|